The Temozolomide Trial for SDH-deficient GIST Patients
GIST is becoming increasingly diverse. SDH-deficient GIST and paragangliomas often occur in adolescents and young adults. Since these SDH mutations are germline, multiple generations of family members are affected.
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego will present a webcast detailing the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
About the Presenter:
Jason K. Sicklick, MD, FACS, is an Associate Professor of Surgery, Division of Surgical Oncology; and Co-Director, Biorepository and Tissue Technology Shared Resource, Moores Cancer Center at the University of California, San Diego, UC San Diego Health Sciences.
Technical Tips to Join Meeting:
- This is a web-only meeting, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.
- Please ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built-in).
- If you are using a mobile device or tablet, in order to view and hear the conference, download the ReadyTalk App from your App store.
Disclaimer:
We cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
